immatics biotechnologies GmbH (4A3) — Cash Flow-to-Debt Ratio
immatics biotechnologies GmbH (4A3) has a Cash Flow-to-Debt Ratio of -0.70x as of June 2026, meaning its operating cash flow of €-60.46 Million could theoretically repay -1% of its total liabilities (€86.11 Million) in one year. See immatics biotechnologies GmbH leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
immatics biotechnologies GmbH Cash Flow-to-Debt Ratio (2019–2025)
Historical debt coverage capacity for immatics biotechnologies GmbH across 7 annual periods. For the full cash flow conversion analysis, see immatics biotechnologies GmbH (4A3) cash conversion ratio.
Annual Cash Flow-to-Debt Ratio for immatics biotechnologies GmbH (2019–2025)
Year-by-year debt coverage analysis for immatics biotechnologies GmbH. Check 4A3 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.26x | €-176.63 Million | €78.24 Million | ▼ -73.3% |
| 2024 | -1.30x | €-158.03 Million | €121.30 Million | ▼ -2136.1% |
| 2023 | 0.06x | €18.23 Million | €284.88 Million | ▼ -87.6% |
| 2022 | 0.51x | €100.13 Million | €194.66 Million | ▼ -22.6% |
| 2021 | 0.66x | €100.13 Million | €150.58 Million | ▼ -0.1% |
| 2020 | 0.67x | €100.13 Million | €150.39 Million | ▲ +64.3% |
| 2019 | 0.41x | €70.97 Million | €175.11 Million | — |